Kapil Dhingra - 13 Nov 2025 Form 4 Insider Report for LAVA Therapeutics NV (LVTX)

Role: Director
Signature: /s/ Amy Garabedian, Attorney-in-Fact
Issuer symbol: LVTX
Transactions as of: 13 Nov 2025
Net transactions value: $0
Form type: 4
Filing time: 17 Nov 2025, 16:30:09 UTC
Previous filing: 19 Aug 2025
Next filing: 11 Dec 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Dhingra Kapil	Director	C/O LAVA THERAPEUTICS N.V., YALELAAN 62, UTRECHT, NETHERLANDS	/s/ Amy Garabedian, Attorney-in-Fact	17 Nov 2025	0001456849

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	LVTX	Common Shares	Disposed to Issuer		-30,000	-100%		0	13 Nov 2025	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	LVTX	Share Options (Right to Buy)	Disposed to Issuer	$0	-33,390	-100%	$0.000000	0	13 Nov 2025	Common Shares	33,390	$0.9300	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Disposed of pursuant to that certain Purchase Agreement, dated August 3, 2025, by and between the Issuer and XOMA Royalty Corporation (as amended, the " Purchase Agreement") in exchange for (i) $1.04 in cash per share (the "Cash Amount"), plus (ii) one non-transferable contingent value right ("CVR") per share.
F2	This option was cancelled pursuant to that certain Purchase Agreement in exchange for cash and CVRs (without interest and net of applicable withholding tax and other applicable deductions) in an amount equal to (i) the excess of $1.04 over the per share exercise price of such option multiplied by the total number of shares underlying such in option and (ii) one CVR per share underlying such in-the-money option.

Content

Disposed of pursuant to that certain Purchase Agreement, dated August 3, 2025, by and between the Issuer and XOMA Royalty Corporation (as amended, the " Purchase Agreement") in exchange for (i) $1.04 in cash per share (the "Cash Amount"), plus (ii) one non-transferable contingent value right ("CVR") per share.

This option was cancelled pursuant to that certain Purchase Agreement in exchange for cash and CVRs (without interest and net of applicable withholding tax and other applicable deductions) in an amount equal to (i) the excess of $1.04 over the per share exercise price of such option multiplied by the total number of shares underlying such in option and (ii) one CVR per share underlying such in-the-money option.